Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide

被引:53
|
作者
Kasapovic, Jelena [1 ]
Pejic, Snezana [1 ]
Stojiljkovic, Vesna [1 ]
Todorovic, Ana [1 ]
Radosevic-Jelic, Ljiljana [2 ]
Saicic, Zorica S. [3 ]
Pajovic, Snezana B. [1 ]
机构
[1] Univ Belgrade, Vinca Inst Nucl Sci, Lab Mol Biol & Endocrinol, Belgrade 11000, Serbia
[2] Univ Belgrade, Inst Oncol & Radiol Serbia, Belgrade, Serbia
[3] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Physiol, Belgrade, Serbia
关键词
Lipid peroxidation; Antioxidants; Breast cancer; Chemotherapy; Radiotherapy; Aging; OXIDATIVE STRESS; PLASMA; RADIOTHERAPY; ADRIAMYCIN; APOPTOSIS; SYSTEM;
D O I
10.1016/j.clinbiochem.2010.08.009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Breast carcinoma is related to the increase of lipid peroxidation in plasma with concomitant decrease of antioxidant (AO) defense capacity in blood cells, which becomes more pronounced during aging of the patients. This work evaluated the potential age-related effect of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) on the level of lipid hydroperoxides (LP), glutathione (GSH), AO enzyme activities of copper, zinc superoxide dismutase (CuZnSOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) in breast cancer patients. The level of CuZnSOD protein was assessed after the FAC therapy and radiotherapy of breast cancer. Design and methods: AO parameters were measured in the blood of 58 breast cancer patients and 60 healthy age-matched healthy subjects by biochemical and Western blot analyses. Results: Increased oxidative stress (LP: p<0.05) and decreased AO enzyme activities (CuZnSOD: p<0.01, GPx: p<0.05, GR: p<0.01) and GSH level (p<0.01) in the blood of breast cancer patients in response to FAC chemotherapy seem not to be age-dependent. CuZnSOD enzyme expression decreased after the FAC chemotherapy (p<0.05), while it increased after the radiotherapy of breast cancer (p<0.05). Conclusion: FAC chemotherapy and radiotherapy promote further oxidative shift, which potentiate already existing chronic oxidative stress linked to breast cancer. In these effects, impaired capacity for H2O2 detoxification (CAT. GPX and GSH) seems to have major contribution. (C) 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 50 条
  • [11] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    Hatam, N.
    Ahmadloo, N.
    Kiadaliri, A. Ahmad
    Bastani, P.
    Askarian, M.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 284 (01) : 215 - 220
  • [12] Longitudinal melanonychia and distal onycholysis associated with 5-fluorouracil/adriamycin/cyclophosphamide chemotherapy for breast cancer
    Zywno, Marta
    Terlikowska-Brzosko, Agnieszka
    Owczarek, Witold
    Szczylik, Cezary
    PRZEGLAD DERMATOLOGICZNY, 2021, 108 (04): : 305 - 310
  • [13] Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer
    Erol, K
    Baltali, E
    Altundag, K
    Guler, N
    Ozisik, Y
    Onat, DA
    Sayek, I
    Cengiz, M
    Atahan, L
    Tekuzman, G
    ONKOLOGIE, 2005, 28 (02): : 81 - 85
  • [14] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    N. Hatam
    N. Ahmadloo
    A. Ahmad Kia Daliri
    P. Bastani
    M. Askarian
    Archives of Gynecology and Obstetrics, 2011, 284 : 215 - 220
  • [15] Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients
    Kajdaniuk, D
    Marek, B
    Kos-Kudla, B
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2001, 26 (04) : 297 - 301
  • [16] Evaluation of Paclitaxel and Carboplatin Versus Combination Chemotherapy with Fluorouracil Doxorubicin and Cyclophosphamide as a Neoadjuvant Therapy in Patients with Inoperable Breast Cancer
    Akhtar, Muhammad Sohail
    Kousar, Farzana
    Masood, Misbah
    Fatimi, Shahab
    Kokab
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2010, 20 (11): : 748 - 752
  • [17] Adjuvant chemotherapy with mitoxantrone cyclophosphamide and 5-fluorouracil in breast cancer: Patient's experience
    Genre, D
    MacquartMoulin, G
    Bouscary, ML
    Viens, P
    Cowen, D
    Comyn, IPY
    Moatti, JP
    Maraninchi, D
    BULLETIN DU CANCER, 1997, 84 (03) : 240 - 246
  • [18] Oral status in patients receiving 5-fluorouracil for colorectal cancer
    Djuric, M.
    Cakic, S.
    Hadzi-Mihailovic, M.
    Petrovic, D.
    Jankovic, L.
    JOURNAL OF BUON, 2010, 15 (03): : 475 - 479
  • [19] Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
    Jamieson, David
    Lee, Jo
    Cresti, Nicola
    Jackson, Rosanna
    Griffin, Melanie
    Sludden, Julieanne
    Verrill, Mark
    Boddy, Alan V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 667 - 674
  • [20] Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control
    Jeffrey M. Albert
    Aman U. Buzdar
    Reina Guzman
    Pamela K. Allen
    Eric A. Strom
    George H. Perkins
    Wendy A. Woodward
    Karen E. Hoffman
    Welela Tereffe
    Kelly K. Hunt
    Thomas A. Buchholz
    Julia L. Oh
    Breast Cancer Research and Treatment, 2011, 128 : 421 - 427